Shares of Neuland Laboratories in Action: Block Deal Worth ₹778.75 Crore

Shares of Neuland Laboratories opened sharply lower in early trade on December 12 following a significant block deal worth ₹778.75 crore on the NSE. The stock plunged to a low of ₹15,605 but showed some recovery. At 10:05 AM, it was trading at Rs 16,334, down 3.74% from the previous close.

Key Highlights of the Block Deal

• Transaction Details: Around 4.9 lakh shares, accounting for 3.8% of the company’s stake, were traded at an average price of ₹15,900 per share. This represents a discount of over 6% compared to the closing price on December 11.
• Volume Surge: Over seven lakh shares were traded on the NSE, significantly exceeding the one-month daily average of 52,000 shares.

Shareholding Insights

The identities of the buyer and seller involved in the block deal remain undisclosed. However, the latest shareholding pattern (as of September 2024) offers some clues:

• Promoter Holding: 32.64%
• FIIs Holding: 26.46%, with key investors being:
  • Malabar India Fund: 6.08%
  • Matthews India Fund: 1.76%
  • Smallcap World Fund, Inc: Increased stake from 1.08% in June to 3.77% in September.

About Neuland Laboratories

Neuland Laboratories is a global leader in API contract development and manufacturing organization (CDMO). The company collaborates with biotechnology and pharmaceutical giants to design, develop, and manufacture complex active pharmaceutical ingredients (APIs).

Their expertise lies in developing small molecules and peptides for clinical trials and commercial manufacturing, ensuring scalability at every stage of the product lifecycle.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.